ArticleBritish journal of cancer2007
Mcm2 predicts recurrence hazard in stage Ta/T1 bladder cancer more accurately than CK20, Ki67 and histological grade.
Article in British journal of cancer, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 68 citations in OpenAlex.
- Prognostic value of ki67 in BCG-treated non-muscle invasive bladder cancer: a meta-analysis and systematic review.BMJ open · 2018Pooled it
- Prediction of Ki-67 expression in bladder cancer based on CT radiomics nomogram.Frontiers in oncology · 2024Article
- MCM2 promotes the stemness and sorafenib resistance of hepatocellular carcinoma cells via hippo signaling.Cell death discovery · 2022Article
- Bioinformatic Analysis of the Expression and Clinical Significance of the DNA Replication Regulator MCM Complex in Bladder Cancer.International journal of general medicine · 2022Article
- Magnetic resonance imaging-based radiomics signature for preoperative prediction of Ki67 expression in bladder cancer.Cancer imaging : the official publication of the International Cancer Imaging Society · 2021Article
- Bioinformatics analysis of differentially expressed genes and pathways in the development of cervical cancer.BMC cancer · 2021Article
- Diagnostic roles of proliferative markers in pathological Grade of T1 Urothelial Bladder Cancer.Journal of Cancer · 2021Article
- Prognostic role of minichromosome maintenance family in multiple myeloma.Cancer gene therapy · 2020Article
- Article
- Expression of E-cadherin, Ki-67, and p53 in urinary bladder cancer in relation to progression, survival, and recurrence.European journal of histochemistry : EJH · 2020Article
- Ki-67 Expression as a Predictive Factor of Muscle Invasion in Bladder Cancer.Open access Macedonian journal of medical sciences · 2018Article
- Distinct Diagnostic and Prognostic Values of Minichromosome Maintenance Gene Expression in Patients with Hepatocellular Carcinoma.Journal of Cancer · 2018Article
- Expression of Minichromosome Maintenance Proteins (MCM) and Cancer Prognosis: A meta-analysis.Journal of Cancer · 2018Article
- Minichromosome maintenance protein 2 correlates with the malignant status and regulates proliferation and cell cycle in lung squamous cell carcinoma.OncoTargets and therapy · 2018Article
- Prognostic value of minichromosome maintenance mRNA expression in early-stage pancreatic ductal adenocarcinoma patients after pancreaticoduodenectomy.Cancer management and research · 2018Article
- Identification of key candidate genes and small molecule drugs in cervical cancer by bioinformatics strategy.Cancer management and research · 2018Article
- ProEx C as Diagnostic Marker for Detection of Urothelial Carcinoma in Urinary Samples: A Review.International journal of medical sciences · 2017Review
- Urinary Bladder Cancer: Biomarkers and Target Therapy, New Era for More Attention.Oncology reviews · 2016Review
- Observational
- New and contemporary markers of prognosis in nonmuscle invasive urothelial cancer.Korean journal of urology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stage Ta/T1 urothelial carcinoma of the bladder (Ta/T1 BC) has a marked tendency to recur. Besides histopathology, markers such as CK20 expression and proliferation index (Ki67) have been shown to predict its clinical course. The replication-licensing factor minichromosome maintenance protein 2 (Mcm2) is a marker of proliferative potential shown to be a promising prognostic marker in various malignancies. The aim of the present study was to evaluate the prognostic value of Mcm2 in comparison to stage, grade, CK20 and Ki67. Initial sporadic Ta/T1 BC (n=71) were evaluated for their expression of CK20, Ki67 and Mcm2 by immunohistochemistry and tissue microarray technology. Prognostic power was analysed by univariate and multivariate Cox regression model for tumour recurrence rate. Median follow-up period was 39 months. A total of 35% patients experienced recurrence. While CK20 was not predictive, grade, Ki67 and Mcm2 were significantly related to recurrence rate in univariate Cox regression model. Only grade (HR 2.37; 95% CI 1.24-4.51; P=0.009) and Mcm2 expression with a cutoff > or = 40% (HR 5.81; 95% CI 2.41-14.00; P<0.001) were independent predictors of recurrence rate in multivariate Cox regression analysis. In addition to grade, expression of Mcm2 is an independent predictor of recurrence in Ta/T1 BC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.